Track Avantor, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Avantor, Inc. AVTR · Stock Open Avantor, Inc. in new tab

15.54 USD
P/E
31.08
EPS
0.50
P/B
1.80
ROE
5.91
Beta
0.95
Target Price
17.35 USD
Avantor, Inc. logo

Avantor, Inc.

🧾 Earnings Recap – Q3 2025

Avantor's third-quarter results reflect a challenging environment, with revenues down 5% year-over-year, but management is optimistic about long-term growth and strategic revitalization efforts.

  • Reported revenue of $1.62 billion, reflecting a 5% decline on an organic basis, primarily due to weaker lab segment performance.
  • Adjusted EBITDA margin held steady at 16.5%, with adjusted EPS of $0.22, down $0.04 year-over-year, underscoring solid cost control amidst challenging conditions.
  • The Board authorized a $500 million share repurchase program, signaling confidence in the company's long-term value and commitment to shareholder returns.
  • Cash generation remains strong, with free cash flow of $172 million, contributing to a conversion rate of 124%.
  • Management highlights significant untapped potential and plans to execute a comprehensive business turnaround strategy, dubbed "Avantor revival."
📅
Loading chart...
Key Metrics
Earnings dateFeb. 10, 2027
P/E31.08
EPS0.50
Book Value8.61
Price to Book1.80
Debt/Equity63.12
% Insiders2.065%
Growth
Revenue Growth0.05%
Earnings Growth-0.37%
Estimates
Forward P/E17.52
Forward EPS0.89
Target Mean Price17.35

DCF valuation

Model fair value for Avantor, Inc. (AVTR)
Result
Sign in to run the valuation for AVTR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
13 analysts · consensus Hold · mean target 17.35 USD (low 16.00, high 19.00) · as of 15 Nov 2026
Low 16.00
Mean 17.35
High 19.00
Price 15.54
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Avantor, Inc. Logo Avantor, Inc. Analysis (AVTR)

United States Materials Official Website Stock

Is Avantor, Inc. a good investment? Avantor, Inc. (AVTR) is currently trading at 15.54 USD. Market analysts have a consensus price target of 17.35 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 31.08. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Avantor, Inc. is expected to release its next earnings report on Feb. 10, 2027. The market consensus estimate for Forward EPS is 0.89.

Investor FAQ

Does Avantor, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Avantor, Inc.?

Avantor, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 10, 2027. The company currently has a trailing EPS of 0.50.

Company Profile

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

Exchange Ticker
NYQ (United States) AVTR
FRA (Germany) AVG.F
STU (Germany) AVG.SG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion